Zydus Cadila receives final approval from USFDA for Nortriptyline Hydrochloride Capsules

Zydus Cadila has received final approval from the USFDA to market Nortriptyline Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg and 75 mg (US RLD: Pamelor Capsules).

This medication is used to treat mental/mood problems such as depression. It may help improve mood and feelings of well-being, relieve anxiety and tension, and increase one's energy level. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 313 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.432.35 as compared to the previous close of Rs. 430.4. The total number of shares traded during the day was 290898 in over 6650 trades.

The stock hit an intraday high of Rs. 438 and intraday low of 412.8. The net turnover during the day was Rs. 124819515.

Source : Equity Bulls

Keywords